Testing the effects of a lactose-free diet on IBS symptoms using breath tests
Official title: Predictive Value of Hydrogen/Methane Lactose Breath Testing on the Therapeutic Effect of Lactose-free Diet in Moderate to Severe ROME IV IBS.
Run by Universitair Ziekenhuis Brussel · NCT04974593 · Data updated 2026-11-12
This study is testing if a lactose-free diet can help people with moderate to severe IBS feel better by using breath tests to see if they have lactose intolerance.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 90 (estimated) |
| Sponsor | Universitair Ziekenhuis Brussel Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Jette, Brussels Capital) |
| Status | Recruiting |
| Started | October 22, 2021 |
| Main results expected | January 1, 2028 |
| Study ends | January 1, 2028 |
| Registry record updated | December 18, 2025 |
| Trial ID | NCT04974593 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are individuals who meet the ROME IV criteria for IBS and have moderate symptom severity while consuming lactose-containing products.
✕Probably not a fit
Patients with known lactose intolerance or other gastrointestinal disorders may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial investigates the predictive value of hydrogen and methane breath testing in patients with moderate to severe Irritable Bowel Syndrome (IBS) who are suspected of having lactose intolerance. The study aims to determine how effective a lactose-free diet is in alleviating IBS symptoms based on breath test results. Participants will undergo breath testing to assess lactose malabsorption and will then follow a lactose-free diet to evaluate symptom improvement. The trial is designed to provide insights into dietary management for IBS patients with lactose intolerance.
Why it matters
Potential benefit: If successful, this study could help patients with IBS better manage their symptoms through tailored dietary recommendations.
How similar studies have gone: Other studies have shown promising results in managing IBS symptoms through dietary interventions, suggesting that this approach may be effective.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Fulfilling the ROME IV criteria for IBS; * Moderate symptom severity as defined by a IBS-SSS \> 175; * Consumption of lactose containing products. Exclusion Criteria: * Clinical suspicion of an organic disorder different from LI or IBS (patients can be included when this disorder had been excluded); * Known lactose intolerance or malabsorption; * Known inflammatory bowel disorder; * Known intestinal motility disorder; * Alcohol (defined as more than 14 U per week) or other substance abuse; * Active psychiatric disorder; * Known systemic or auto-immune disorder with implication for the GI system; * Prior abdominal surgery (with the exception of appendectomy); * Any prior diagnosis of cancer other than basocellular carcinoma; * Current chemotherapy; * History of gastro-enteritis in the past 8 weeks; * Intake of antibiotics, pre- or probiotics during the past 8 weeks; * Dietary supplements unless taken at a stable dose for more than 8 weeks; * Treatment with neuromodulators (one neuromodulator taken at a stable dose for more than 12 weeks is allowed); * Treatment with spasmolytic agents, opioids, loperamide, gelatin tannate or mucoprotect-ants during the past 8 weeks; * LFD or low FODMAP diet in the past
Where it's running
-
UZ Brussel
Jette, Brussels Capital, Belgium Recruiting
Study contacts
- Study coordinator: Sébastien Kindt, MD
- Email: Sebastien.kindt@uzbrussel.be
- Phone: +32 2 476
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Liver Fat and Scarring in People Suspected of Non-Celiac Wheat Sensitivity
This study looks to see if people with non-celiac wheat sensitivity have liver fat or fibrosis and how this relates to IBS/FD and celiac disease.
-
Repeated transcranial magnetic stimulation to treat diarrhea-predominant irritable bowel syndrome
This study will test whether repeated transcranial magnetic stimulation (rTMS) can reduce diarrhea, abdominal pain, and improve quality of life in adults with IBS-D.
-
Brenipatide (LY3537031) for IBS with constipation
This trial will test whether brenipatide (LY3537031), given by a small under-the-skin injection, helps adults with IBS-C have less belly pain and more normal bowel movements compared with a placebo.
-
Brenipatide (LY3537031) treatment for adults with IBS‑D
This will test whether brenipatide (LY3537031) given under the skin helps adults with IBS‑D reduce belly pain and improve stool consistency compared with placebo.
-
Camlipixant for IBS-D and IBS-M: a test in adults
This study tests camlipixant versus placebo in adults with IBS with diarrhea or mixed IBS to see if it helps reduce symptoms and is safe.
-
Defining Objective Markers of Dietary Compliance in IBS
This study tests whether a biomarker in stool or urine can reflect how much certain carbohydrates you eat, helping manage IBS.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.